Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension Trial of TransCon CNP in Children and Adolescents With Achondroplasia
NCT05929807Phase 3Enrolling by invitation
- Sponsor
- Ascendis Pharma
- Start
- Jun 2023
- Primary completion
- Jan 2039
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
A Phase 3 trial of navepegritide in achondroplasia (ACH), sponsored by Ascendis Pharma. Started Jun 2023; status: enrolling by invitation.
02
Drugs
navepegritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT05929807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05929807.